SIRPA and neoplasm: Groups of B16-F10-bearing mice were administered either PBS (n = 7), 1 × 108 PFU NDV-Luc (n = 6), NDV-αCD47 (n = 6), NDV-SIRPα-Fc (n = 8), NDV-Luc in combination with 50 μg anti-CD47 given independently (n = 8), 50 μg anti-CD47 antibody alone (n = 8), or 50 μg of an isotype control alone (n = 7) (Figure 3A), and tumor volume was monitored over time.